Hutchison China MediTech Limited (LON:HCM) Stock Rating Reaffirmed by Beaufort Securities

Hutchison China MediTech Limited (LON:HCM)‘s stock had its “buy” rating reaffirmed by analysts at Beaufort Securities in a note issued to investors on Tuesday, August 1st.

Receive News & Ratings for Hutchison China MediTech Limited Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Separately, Panmure Gordon restated a “buy” rating and issued a GBX 3,530 ($45.83) target price on shares of Hutchison China MediTech Limited in a research note on Thursday, June 22nd.

Hutchison China MediTech Limited (LON:HCM) traded down 0.13% during mid-day trading on Tuesday, reaching GBX 3770.00. The company had a trading volume of 59,532 shares. Hutchison China MediTech Limited has a 52 week low of GBX 1,760.00 and a 52 week high of GBX 372,000.00. The firm’s market capitalization is GBX 2.29 billion. The stock’s 50-day moving average price is GBX 13,408.90 and its 200 day moving average price is GBX 5,588.43.

TRADEMARK VIOLATION NOTICE: “[[title]]” was originally reported by [[site]] and is the property of of [[site]]. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at [[permalink]].

In related news, insider Karen Jean Ferrante acquired 10,000 shares of Hutchison China MediTech Limited stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average price of GBX 3,475 ($45.11) per share, for a total transaction of £347,500 ($451,122.94).

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.